(Q43047825)

12 November 2017

Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology (English)

1 reference

12 November 2017

1 reference

1 reference

7

Jacques Izopet

1 reference

12 November 2017

8

Lionel Rostaing

1 reference

12 November 2017

1

Nassim Kamar

1 reference

12 November 2017

2

Karine Sandres-Saune

1 reference

12 November 2017

5

Olivier Cointault

1 reference

12 November 2017

3

Janick Selves

1 reference

12 November 2017

David Ribes

4

1 reference

PubMed ID

12830471

12 November 2017

Dominique Durand

series ordinal

6

1 reference

PubMed ID

12830471

12 November 2017

language of work or name

1 reference

1 July 2003

1 reference

American Journal of Kidney Diseases

12 November 2017

1 reference

12 November 2017

42

1 reference

12 November 2017

184-192

1 reference

12 November 2017

1

1 reference

Hepatitis C virus infection and renal transplantation

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Glomerular disease during HCV infection in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Long-term outcome of hepatitis C infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Impact of hepatitis B and C virus on kidney transplantation outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Glomerular diseases in patients with hepatitis C virus infection after renal transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Interferon treatment for chronic hepatitis C virus infection in uremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

The tolerance and efficacy of interferon‐α in haemodialysis patients with HCV infection: a multicentre, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Hepatitis C virus infection in kidney transplantation and a pilot study of the effects of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Ribavirin therapy for hepatitis C infection following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Immunological and virological effects of ribavirin in hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Inhibition of immune functions by antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Hepatitis C virus infection in dialysis and renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

A prospective study of hepatitis C virus infection in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Evolution of hepatitis C virus quasispecies in renal transplant patients with de novo glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900422-0

7 January 2021

10.1016/S0272-6386(03)00422-0

Identifiers

DOI

1 reference

12 November 2017

1 reference

PubMed ID

12830471